Skip to main content
Premium Trial:

Request an Annual Quote

Merck To Use Morphosys' HuCAL Gold Antibodies in Vaccine Research

Premium

German biotech firm Morphosys said this week its diagnostic antibody unit AbD Serotec has amended its existing license agreement with Merck to include use of its HuCAL Gold technology for vaccine research.

The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.

AbD Serotec will receive annual user fees from Merck for access to the HuCAL technology and license fees for clinical monitoring reagents.

Merck and Morphosys's original agreement began in 2005 when Merck licensed the firm's HuCAL GOLD and AutoCAL technologies for research and development of human therapeutic antibodies.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.